Skip to main content
In stock | Immunotherapy (Investigational Checkpoint)

Volrustomig

Oncology Type Solid Tumour
Drug Class / Mechanism Bispecific Checkpoint Antibody, PD-1 x CTLA-4
No Image
Description

Volrustomig is classified as a Bispecific Checkpoint Antibody, PD-1 x CTLA-4, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational Checkpoint)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3